Forte Biosciences (NASDAQ:FBRX – Get Free Report) will likely be releasing its earnings data before the market opens on Monday, March 17th. Analysts expect Forte Biosciences to post earnings of ($4.55) per share for the quarter.
Forte Biosciences Stock Performance
FBRX opened at $5.80 on Friday. The business has a 50 day moving average price of $12.50 and a 200 day moving average price of $11.61. Forte Biosciences has a twelve month low of $4.11 and a twelve month high of $28.68. The firm has a market cap of $37.08 million, a P/E ratio of -0.36 and a beta of 2.35.
Wall Street Analyst Weigh In
Several research firms recently weighed in on FBRX. TD Cowen began coverage on Forte Biosciences in a report on Tuesday, January 21st. They issued a “buy” rating for the company. Chardan Capital restated a “buy” rating and issued a $64.00 target price on shares of Forte Biosciences in a report on Wednesday, December 4th.
Forte Biosciences Company Profile
Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.
Read More
- Five stocks we like better than Forte Biosciences
- How to Plot Fibonacci Price Inflection Levels
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- How to Invest in Small Cap Stocks
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Forte Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forte Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
